期刊论文详细信息
The oncologist
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
article
Julio Delgado1  Malgorzata Zienowicz1  Paula Boudewina van Hennik3  Alexandre Moreau3  Christian Gisselbrecht6  Harald Enzmann3  Francesco Pignatti1 
[1] Oncology and Hematology Office, European Medicines Agency;Department of Hematology, Hospital Clinic;Committe for Medicinal Products for Human Use, European Medicines Agency;College ter Beoordeling van Geneesmiddelen;Agence Nationale de Securite du Medicament et des Produits de Sante;Hopital Saint Louis;Bundesinstitut für Arzneimittel und Medizinprodukte
关键词: Multiple myeloma;    Isatuximab;    Pomalidomide;    Dexamethasone;    EMA • Anti-CD38 antibody;   
DOI  :  10.1002/onco.13892
学科分类:地质学
来源: AlphaMed Press Incorporated
PDF
【 摘 要 】

Isatuximab is a monoclonal antibody that binds to the human CD38 antigen. On May 30, 2020, a marketing authorization valid through the European Union (EU) was issued for isatuximab in combination with pomalidomide and dexamethasone (IsaPd) for the treatment of adult patients with relapsed and refractory (RR) multiple myeloma (MM). The recommended dose of isatuximab was 10 mg/kg, administered intravenously weekly at cycle 1 and then biweekly in subsequent 28-day cycles. Isatuximab was evaluated in a phase III, open-label, multicenter, randomized trial that randomly allocated IsaPd versus pomalidomide plus dexamethasone (Pd) to adult patients with RR MM. The primary endpoint of the trial was progression-free survival, as assessed by an independent review committee, which was superior for the IsaPd arm (hazard ratio, 0.596; 95% confidence interval, 0.436–0.814; p  = .001) compared with the Pd arm. Treatment with IsaPd led to higher incidences of treatment-related adverse events (AEs), grade ≥ 3 AEs, and serious AEs compared with Pd treatment. Most frequently observed AEs that occurred more often in the IsaPd arm were infusion-related reactions, infections, respiratory AEs, neutropenia (including neutropenic complications), and thrombocytopenia. The aim of this article is to summarize the scientific review of the application leading to regulatory approval in the EU. Implications for Practice Isatuximab was approved in the European Union, in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have already received therapy but whose disease did not respond or relapsed afterward. The addition of isatuximab resulted in a clinically meaningful and significant prolongation of the time from treatment initiation to further disease relapse or patient's death. The safety profile was considered acceptable, and the benefit-risk ratio was determined to be positive.

【 授权许可】

CC BY|CC BY-NC   

【 预 览 】
附件列表
Files Size Format View
RO202302050003726ZK.pdf 410KB PDF download
  文献评价指标  
  下载次数:3次 浏览次数:0次